A promising new drug is available for metastatic breast cancer patient, it is called ” Tykerb”. It is a once daily drug. It has minimum side effects just like diarrhoea and rashes. It attacks the proliferating cancer cells. No hospitalisation is required. Clinical trials are going on in Boston, USA.
It is very useful in advanced breast cancer patients who had stopped responding to the drug “Herceptin” and were out of treatment options.
Unlike other breast cancer drugs used for advanced cases, it shows minimum effects on heart. It is a definitely promosing new treatment for metastatic breast cancer patients where death rates are very high.
Tykerb is an orally bioavailable small molecule which potently inhibits, two receptors, ErbB2 and ErbB1, and is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.
Breast cancer is the most common major cancer in American women and the second leading cause of cancer deaths in women. About 1 million new breast cancer cases are expected to have diagnosed in 2006 of which 2,00,000 cases in america alone.
Related posts:
- FDA approved Avastin for Breast Cancer Food and Drug Administration approved Genentech’s “Avastin” for the treatment of advanced breast Cancer. Avastin was already got FDA approval for treating advanced Colon and non-small cell Lung cancer....
- FDA approved Wyeth drug Torisel for renal cell carcinoma Food and Drug Administration (FDA) approved Wyeth drug, Temsirolimus (Torisel), for the treatment of advanced kidney cancer, renal cell carcinoma. According to company research, it has shown better results...
- New drug hope for Breast cancer patients “Olaparib” is the new drug that is creating lot of hope among inherited Breast and Ovarian cancer patients. Drug succeeded in reducing the size of tumours in 40%...
- Evista for Breast Cancer in postmenopausal women Evista (Raloxifene) was approved for Breast cancer treatment by Food and Drug administration for some post-menopausal women. After Tamoxifen, Evista is the second drug approved for breast cancer treatment....
- Taxotere approved for head and neck cancer by FDA French Pharma Company Sanofil-Aventis’s Taxotere (Docetaxel) got US FDA (Food and Drug Administration) approval for treating head and neck cancer. FDA approved Docetaxel for treating locally advanced head and...
Recent Comments